

Philippa Clare Matthews

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4328337/publications.pdf>

Version: 2024-02-01

170
papers

10,887
citations

50276

46
h-index

43889

91
g-index

248
all docs

248
docs citations

248
times ranked

16143
citing authors

#	ARTICLE	IF	CITATIONS
1	An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. <i>Clinical Infectious Diseases</i> , 2022, 74, 1208-1219.	5.8	64
2	Changes in paediatric respiratory infections at a UK teaching hospital 2016–2021; impact of the SARS-CoV-2 pandemic. <i>Journal of Infection</i> , 2022, 84, 40-47.	3.3	42
3	Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity in the General Population in the United Kingdom. <i>Clinical Infectious Diseases</i> , 2022, 75, e329-e337.	5.8	20
4	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e21-e31.	7.3	131
5	Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers. <i>Journal of Biological Rhythms</i> , 2022, 37, 124-129.	2.6	42
6	Monitoring populations at increased risk for SARS-CoV-2 infection in the community using population-level demographic and behavioural surveillance. <i>Lancet Regional Health - Europe</i> , The, 2022, 13, 100282.	5.6	11
7	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. <i>Nature Medicine</i> , 2022, 28, 1072-1082.	30.7	147
8	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	12.8	20
9	A call for advocacy and patient voice to eliminate hepatitis B virus infection. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 282-285.	8.1	7
10	Spacer Domain in Hepatitis B Virus Polymerase: Plugging a Hole or Performing a Role?. <i>Journal of Virology</i> , 2022, 96, e0005122.	3.4	4
11	Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers. <i>Clinical and Experimental Immunology</i> , 2022, 209, 90-98.	2.6	5
12	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. <i>JCI Insight</i> , 2022, 7, .	5.0	24
13	SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection. <i>Nature Communications</i> , 2022, 13, .	12.8	6
14	Estimating hepatitis B virus cccDNA persistence in chronic infection. <i>Virus Evolution</i> , 2021, 7, veaa063.	4.9	18
15	Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 493-507.	2.0	42
16	Extending treatment eligibility for chronic hepatitis B virus infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 146-147.	17.8	34
17	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	30.7	265
18	Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. <i>New England Journal of Medicine</i> , 2021, 384, 533-540.	27.0	803

#	ARTICLE	IF	CITATIONS
19	Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. <i>Lancet Public Health</i> , The, 2021, 6, e30-e38.	10.0	147
20	Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections. <i>BMC Infectious Diseases</i> , 2021, 21, 187.	2.9	23
21	Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. <i>Aids</i> , 2021, 35, F1-F10.	2.2	67
22	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 1951.	12.8	54
23	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	12.8	102
24	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 763-772.	10.7	301
25	Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. <i>Aids</i> , 2021, 35, 1597-1604.	2.2	2
26	Early Initiation of Antiretroviral Therapy Following In Utero HIV Infection Is Associated With Low Viral Reservoirs but Other Factors Determine Viral Rebound. <i>Journal of Infectious Diseases</i> , 2021, 224, 1925-1934.	4.0	9
27	Diagnosis of SARS-CoV-2 Infection with LamPORE, a High-Throughput Platform Combining Loop-Mediated Isothermal Amplification and Nanopore Sequencing. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	30
28	Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1110-1120.	2.0	12
29	Quantitative SARS-CoV-2 anti-spike responses to Pfizerâ€™BioNTech and Oxfordâ€™AstraZeneca vaccines by previous infection status. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1516.e7-1516.e14.	6.0	100
30	COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing. <i>EClinicalMedicine</i> , 2021, 36, 100924.	7.1	162
31	Equity for excellence in academic institutions: a manifesto for change. <i>Wellcome Open Research</i> , 2021, 6, 142.	1.8	6
32	Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 610.	2.9	9
33	Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. <i>Nature Medicine</i> , 2021, 27, 1370-1378.	30.7	260
34	Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season. <i>Eurosurveillance</i> , 2021, 26, .	7.0	17
35	Ct threshold values, a proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across populations and over time. <i>ELife</i> , 2021, 10, .	6.0	91
36	Cuts to UK official development assistance budget jeopardise global viral hepatitis elimination goals. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 527-528.	8.1	0

#	ARTICLE	IF	CITATIONS
37	Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019. <i>Hepatology Communications</i> , 2021, 5, 1586-1604.	4.3	7
38	Endemic HBV among hospital in-patients in Bangladesh, including evidence of occult infection. <i>Journal of General Virology</i> , 2021, 102, .	2.9	2
39	Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. <i>Nature Microbiology</i> , 2021, 6, 1140-1149.	13.3	254
40	Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era. <i>Frontiers in Medicine</i> , 2021, 8, 706482.	2.6	23
41	Viral detection and identification in 20Âmin by rapid single-particle fluorescence in-situ hybridization of viral RNA. <i>Scientific Reports</i> , 2021, 11, 19579.	3.3	16
42	Epidemiological data and genome sequencing reveals that nosocomial transmission of SARS-CoV-2 is underestimated and mostly mediated by a small number of highly infectious individuals. <i>Journal of Infection</i> , 2021, 83, 473-482.	3.3	55
43	The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection. <i>BMJ Global Health</i> , 2021, 6, e004275.	4.7	51
44	The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2021, 73, e699-e709.	5.8	235
45	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	28.9	262
46	Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. <i>Nature Medicine</i> , 2021, 27, 2127-2135.	30.7	450
47	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. <i>Nature Communications</i> , 2021, 12, 6250.	12.8	88
48	Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. , 2021, , .		2
49	Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom. <i>New England Journal of Medicine</i> , 2021, 385, 2582-2585.	27.0	49
50	Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults. <i>Journal of Clinical Virology</i> , 2020, 129, 104548.	3.1	16
51	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1390-1400.	9.1	336
52	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. <i>PLoS ONE</i> , 2020, 15, e0238839.	2.5	3
53	Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort. <i>Journal of Infection</i> , 2020, 81, 121-130.	3.3	16
54	HIGH-FREQUENCY failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal needs causing maternal NON-ADHERENCE. <i>EClinicalMedicine</i> , 2020, 22, 100344.	7.1	23

#	ARTICLE	IF	CITATIONS
55	Microbial aetiology of brain abscess in a UK cohort: Prominent role of <i>Streptococcus intermedius</i> . <i>Journal of Infection</i> , 2020, 80, 623-629.	3.3	29
56	Nanopore metagenomic sequencing to investigate nosocomial transmission of human metapneumovirus from a unique genetic group among haematology patients in the United Kingdom. <i>Journal of Infection</i> , 2020, 80, 571-577.	3.3	15
57	Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors. <i>BMJ Open</i> , 2020, 10, e032890.	1.9	13
58	Hepatitis B virus seroepidemiology data for Africa: Modelling intervention strategies based on a systematic review and meta-analysis. <i>PLoS Medicine</i> , 2020, 17, e1003068.	8.4	39
59	Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection. <i>Nature Communications</i> , 2020, 11, 1767.	12.8	15
60	Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection. <i>Wellcome Open Research</i> , 2020, 5, 240.	1.8	2
61	Analysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequences. <i>Journal of General Virology</i> , 2020, 101, 271-283.	2.9	38
62	National Institute for Health Research Health Informatics Collaborative: development of a pipeline to collate electronic clinical data for viral hepatitis research. <i>BMJ Health and Care Informatics</i> , 2020, 27, e100145.	3.0	14
63	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , 2020, 5, 139.	1.8	179
64	Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa. <i>Wellcome Open Research</i> , 2020, 5, 113.	1.8	9
65	Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms. <i>Wellcome Open Research</i> , 2020, 5, 151.	1.8	10
66	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	1.8	81
67	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	1.8	122
68	SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. <i>Eurosurveillance</i> , 2020, 25, .	7.0	17
69	Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. <i>ELife</i> , 2020, 9, .	6.0	196
70	Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa. <i>Wellcome Open Research</i> , 2020, 5, 113.	1.8	5
71	Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection. <i>Wellcome Open Research</i> , 2020, 5, 240.	1.8	3
72	Case Report: Disseminated, rifampicin resistant <i>Mycobacterium bovis</i> (BCG) infection in an immunocompromised child. <i>Wellcome Open Research</i> , 2020, 5, 242.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Title is missing!. , 2020, 17, e1003068.		0
74	Title is missing!. , 2020, 17, e1003068.		0
75	Title is missing!. , 2020, 17, e1003068.		0
76	Title is missing!. , 2020, 17, e1003068.		0
77	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
78	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
79	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
80	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
81	Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa. BMC Public Health, 2019, 19, 829.	2.9	17
82	Oral versus Intravenous Antibiotics for Bone and Joint Infection. New England Journal of Medicine, 2019, 380, 425-436.	27.0	548
83	Insights From Deep Sequencing of the HBV Genome—Unique, Tiny, and Misunderstood. Gastroenterology, 2019, 156, 384-399.	1.3	92
84	Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection. MBio, 2019, 10, .	4.1	24
85	Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV). Scientific Reports, 2019, 9, 7081.	3.3	75
86	HBV vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical cohort and dynamic model. BMC Medicine, 2019, 17, 43.	5.5	15
87	Metagenomic Nanopore Sequencing of Influenza Virus Direct from Clinical Respiratory Samples. Journal of Clinical Microbiology, 2019, 58, .	3.9	121
88	A Study of Knowledge, Experience, and Beliefs About Hepatitis B Virus (HBV) Infection in South Western Uganda. Frontiers in Public Health, 2019, 7, 304.	2.7	13
89	Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT. Health Technology Assessment, 2019, 23, 1-92.	2.8	27
90	FAIR data needed to liberate hepatitis B virus (HBV) from the catch-22 of neglect. Journal of Global Health, 2019, 9, 010310.	2.7	1

#	ARTICLE	IF	CITATIONS
91	Oxford Screening CSF and Respiratory samples (â€ˆOSCARâ€™): results of a pilot study to screen clinical samples from a diagnostic microbiology laboratory for viruses using Illumina next generation sequencing. BMC Research Notes, 2018, 11, 120.	1.4	6
92	A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection - A systematic review. Wellcome Open Research, 2018, 3, 29.	1.8	53
93	A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection - A systematic review. Wellcome Open Research, 2018, 3, 29.	1.8	46
94	Major TCR Repertoire Perturbation by Immunodominant HLA-B*44:03-Restricted CMV-Specific T Cells. Frontiers in Immunology, 2018, 9, 2539.	4.8	25
95	Detection of Viral Pathogens With Multiplex Nanopore MinION Sequencing: Be Careful With Cross-Talk. Frontiers in Microbiology, 2018, 9, 2225.	3.5	75
96	Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. BMC Infectious Diseases, 2018, 18, 461.	2.9	19
97	Recovery of effective HIV-specific CD4+ T-cell activity following antiretroviral therapy in paediatric infection requires sustained suppression of viraemia. Aids, 2018, 32, 1413-1422.	2.2	9
98	Multiplex PCR reveals high prevalence of enterovirus and HHV6 in acellular paediatric cerebrospinal fluid samples. Journal of Infection, 2018, 77, 249-257.	3.3	23
99	A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action. PLoS Neglected Tropical Diseases, 2018, 12, e0006629.	3.0	55
100	Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen. Frontiers in Immunology, 2018, 9, 1561.	4.8	33
101	Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient. Retrovirology, 2018, 15, 7.	2.0	13
102	Metalware-associated orthopaedic infections caused by Staphylococcus lugdunensis : An emerging pathogen. Journal of Infection, 2017, 75, 368-370.	3.3	8
103	Role of HIV-specific CD8+ T cells in pediatric HIV cure strategies after widespread early viral escape. Journal of Experimental Medicine, 2017, 214, 3239-3261.	8.5	31
104	Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. The Lancet Global Health, 2017, 5, e992-e1003.	6.3	93
105	HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. Journal of Virology, 2017, 91, .	3.4	14
106	Hepatitis B vaccine shortage: another symptom of chronic neglect?. BMJ: British Medical Journal, 2017, 359, j4686.	2.3	3
107	Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities. PLoS ONE, 2017, 12, e0184496.	2.5	2
108	Human parvovirus 4 â€™PARV4â€™ remains elusive despite a decade of study. F1000Research, 2017, 6, 82.	1.6	17

#	ARTICLE	IF	CITATIONS
109	PARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multicentre African cohort. Wellcome Open Research, 2017, 2, 26.	1.8	11
110	Hepatitis B virus infection as a neglected tropical disease. PLoS Neglected Tropical Diseases, 2017, 11, e0005842.	3.0	79
111	Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations. PLoS ONE, 2017, 12, e0189612.	2.5	24
112	Subdominant Gag-specific anti-HIV efficacy in an HLA-B*57-positive elite controller. Aids, 2016, 30, 972-974.	2.2	4
113	Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infectious Diseases, 2016, 16, 556.	2.9	53
114	Screening, characterisation and prevention of Hepatitis B virus (HBV) co-infection in HIV-positive children in South Africa. Journal of Clinical Virology, 2016, 85, 71-74.	3.1	19
115	Lower Viral Loads and Slower CD4 ⁺ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02. Journal of Infectious Diseases, 2016, 214, 379-389.	4.0	6
116	HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults. Journal of Infectious Diseases, 2016, 213, 1248-1252.	4.0	9
117	FAIRness in scientific publishing. F1000Research, 2016, 5, 2816.	1.6	4
118	Fairness in scientific publishing. F1000Research, 2016, 5, 2816.	1.6	4
119	Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus. Wellcome Open Research, 2016, 1, 9.	1.8	23
120	Disease progression despite protective HLA expression in an HIV-infected transmission pair. Retrovirology, 2015, 12, 55.	2.0	11
121	Human Parvovirus 4 Infection among Mothers and Children in South Africa. Emerging Infectious Diseases, 2015, 21, 713-715.	4.3	10
122	Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era. Frontiers in Microbiology, 2015, 6, 1016.	3.5	101
123	Sex Differences in Antiretroviral Therapy Initiation in Pediatric HIV Infection. PLoS ONE, 2015, 10, e0131591.	2.5	19
124	Prevalence and Characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South Africa and Botswana. PLoS ONE, 2015, 10, e0134037.	2.5	49
125	Screening and treatment for hepatitis C: a balanced perspective. BMJ, The, 2015, 350, h644-h644.	6.0	4
126	HLA contributes to immune control of hepatitis B in HIV-positive African adults. Journal of Infection, 2015, 71, 685-686.	3.3	0

#	ARTICLE	IF	CITATIONS
127	Rolling back malaria. <i>ELife</i> , 2015, 4, .	6.0	0
128	PARV4: An Emerging Tetraparvovirus. <i>PLoS Pathogens</i> , 2014, 10, e1004036.	4.7	26
129	Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E5393-400.	7.1	85
130	HIV Subtype Influences HLA-B*07:02-Associated HIV Disease Outcome. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 468-475.	1.1	19
131	Increased teicoplanin doses are associated with improved serum levels but not drug toxicity. <i>Journal of Infection</i> , 2014, 68, 43-49.	3.3	28
132	HIV Minor Variants Detected by Next Generation Sequencing: Impact on Immune Control of HIV in the Context of HLA-B*27:05 and HLA-B*57:01. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A180-A181.	1.1	0
133	Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa. <i>Journal of Clinical Virology</i> , 2014, 61, 20-33.	3.1	138
134	Electronic prescribing: Reducing delay to first dose of antibiotics for patients in intensive care. <i>BMJ Quality Improvement Reports</i> , 2013, 2, u202241.w1120.	0.8	3
135	Nef-Specific CD8+ T Cell Responses Contribute to HIV-1 Immune Control. <i>PLoS ONE</i> , 2013, 8, e73117.	2.5	36
136	HLA-B*57 Micropolymorphism Shapes HLA Allele-Specific Epitope Immunogenicity, Selection Pressure, and HIV Immune Control. <i>Journal of Virology</i> , 2012, 86, 919-929.	3.4	66
137	Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope. <i>Journal of Virology</i> , 2012, 86, 12643-12654.	3.4	49
138	Co-Operative Additive Effects between HLA Alleles in Control of HIV-1. <i>PLoS ONE</i> , 2012, 7, e47799.	2.5	20
139	Acute Necrotizing Sinusitis Caused by <i>Staphylococcus lugdunensis</i> : Fig. 1. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2740-2742.	3.9	15
140	Banting Memorial Lecture 2010^{âˆ“}. Type 2 diabetes as an âˆ“infectiousâˆ“™ disease: is this the Black Death of the 21st century?. <i>Diabetic Medicine</i> , 2011, 28, 2-9.	2.3	43
141	Banting Memorial Lecture: reply from Matthews and Matthews. Typeâˆ“2 diabetes as an âˆ“infectiousâˆ“™ disease: is this the Black Death of the 21st century?. <i>Diabetic Medicine</i> , 2011, 28, 880-880.	2.3	0
142	The Hypervariable HIV-1 Capsid Protein Residues Comprise HLA-Driven CD8+ T-Cell Escape Mutations and Covarying HLA-Independent Polymorphisms. <i>Journal of Virology</i> , 2011, 85, 1384-1390.	3.4	26
143	HLA-A*7401âˆ“Mediated Control of HIV Viremia Is Independent of Its Linkage Disequilibrium with HLA-B*5703. <i>Journal of Immunology</i> , 2011, 186, 5675-5686.	0.8	49
144	Additive Contribution of HLA Class I Alleles in the Immune Control of HIV-1 Infection. <i>Journal of Virology</i> , 2010, 84, 9879-9888.	3.4	148

#	ARTICLE	IF	CITATIONS
145	Chapter 1 HLA-Mediated Control of HIV and HIV Adaptation to HLA. <i>Advances in Parasitology</i> , 2009, 68, 1-20.	3.2	7
146	HLA Footprints on Human Immunodeficiency Virus Type 1 Are Associated with Interclade Polymorphisms and Intraclade Phylogenetic Clustering. <i>Journal of Virology</i> , 2009, 83, 4605-4615.	3.4	40
147	Adaptation of HIV-1 to human leukocyte antigen class I. <i>Nature</i> , 2009, 458, 641-645.	27.8	408
148	Inter-Continental Patterns of HIV-1 Control: HLA and the Quest for a T Cell Vaccine. <i>Journal of Infection</i> , 2009, 59, S430-S431.	3.3	0
149	Diagnosis and management of prosthetic joint infection. <i>BMJ: British Medical Journal</i> , 2009, 338, b1773-b1773.	2.3	137
150	Muscle hemorrhage in a paraplegic adult with neurofibromatosis type 1 and an associated vasculopathy. <i>American Journal of Medical Genetics, Part A</i> , 2008, 146A, 2424-2426.	1.2	1
151	Native hip joint septic arthritis in 20 adults: Delayed presentation beyond three weeks predicts need for excision arthroplasty. <i>Journal of Infection</i> , 2008, 57, 185-190.	3.3	35
152	<i>Staphylococcus lugdunensis</i> endocarditis following cardiac catheterisation. <i>International Journal of Cardiology</i> , 2008, 130, 87-88.	1.7	14
153	Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. <i>Journal of Experimental Medicine</i> , 2008, 205, 1009-1017.	8.5	203
154	HLA Class I-Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load. <i>Journal of Virology</i> , 2008, 82, 6434-6446.	3.4	126
155	Phylogenetic Dependency Networks: Inferring Patterns of CTL Escape and Codon Covariation in HIV-1 Gag. <i>PLoS Computational Biology</i> , 2008, 4, e1000225.	3.2	116
156	Central Role of Reverting Mutations in HLA Associations with Human Immunodeficiency Virus Set Point. <i>Journal of Virology</i> , 2008, 82, 8548-8559.	3.4	152
157	Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 356-362.	3.0	138
158	Clinical management of diabetic foot infection: diagnostics, therapeutics and the future. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 117-127.	4.4	12
159	Misdiagnosing Melioidosis. <i>Emerging Infectious Diseases</i> , 2007, 13, 349-351.	4.3	16
160	Teicoplanin levels in bone and joint infections: Are standard doses subtherapeutic?. <i>Journal of Infection</i> , 2007, 55, 408-413.	3.3	27
161	Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2006, 80, 3617-3623.	3.4	408
162	HIV testing for adult patients with <i>Streptococcus pneumoniae</i> bacteraemia. <i>Clinical Medicine</i> , 2006, 6, 512-512.	1.9	0

#	ARTICLE	IF	CITATIONS
163	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	20
164	Inhaled Budesonide in the Treatment of Early COVID-19 Illness: A Randomised Controlled Trial. SSRN Electronic Journal, 0, , .	0.4	1
165	Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA Vaccine. SSRN Electronic Journal, 0, , .	0.4	21
166	Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Research, 0, 7, 32.	1.8	4
167	Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. Wellcome Open Research, 0, 7, 51.	1.8	0
168	Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Research, 0, 7, 32.	1.8	2
169	Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Research, 0, 7, 32.	1.8	8
170	Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset. International Journal of Epidemiology, 0, , .	1.9	2